In vitro characteristics of a gelling PEGDA-QT polymer system with model drug release for cerebral aneurysm embolization.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23749590.
- Also identified by DOI 10.1002/jbmb.32969.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A liquid-to-solid gelling polymer system, such as the poly(ethylene glycol) diacrylate-pentaerythritol tetrakis (3-mercaptopropionate) (PEGDA-QT) system, can fill cerebral aneurysms more completely than current embolization materials, reducing the likelihood of aneurysm recurrence. PEGDA-QT gels were formulated using PEGDA of different molecular weights (PEGDA<sub>575</sub> and PEGDA<sub>700</sub> ), and their characteristics were examined in vitro. Experiments examined gel time, mass change, crosslink integrity, cytotoxicity, and protein release capabilities. In general, PEGDA<sub>575</sub> -QT gels were more hydrophobic, requiring an initiating solution with a higher pH (pH 9.5) to achieve a gel time comparable to PEGDA<sub>700</sub> -QT gels, which used an initiating solution at pH 9.19. The mass change and crosslink integrity of gels were analyzed over time after gels were submerged in 150 mM phosphate buffered saline. After 380 days, PEGDA<sub>575</sub> -QT gels achieved a maximum mass increase of 72% due to water uptake, while PEGDA<sub>700</sub> -QT gels doubled their initial mass (100% increase) by 165 days. Compression tests showed that PEGDA<sub>700</sub> -QT gels hydrolyzed more quickly than PEGDA<sub>575</sub> -QT gels. Cytotoxicity assays showed that in general, PEGDA<sub>575</sub> -QT negatively affected cell growth, while PEGDA<sub>700</sub> -QT gels promoted cell viability. Sustained, controlled release of lysozyme, a 14.3 kDa protein, was achieved over an 8-week period when loaded into PEGDA<sub>700</sub> -QT gels, but PEGDA<sub>575</sub> -QT gels did not show sustained release. These studies show that although they are similar in composition, these PEGDA-QT gel formulations behave considerably differently. Although PEGDA<sub>700</sub> -QT gels swell more and degrade faster than PEGDA<sub>575</sub> -QT gels, their cytocompatibility and protein release characteristics may prove to be more beneficial for in vivo aneurysm treatment. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2013.